Supply of products by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and standards of therapeutic goods in Australia, addressing the need for a cohesive and effective system to ensure public health and safety through the quality, efficacy, and safety of therapeutic goods. The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to provide for the regulation of therapeutic goods and to ensure that these goods meet appropriate standards of quality, efficacy, and safety. The policy objective of the Act is to protect and promote public health by controlling the quality and supply of therapeutic goods. The Act grants the Secretary of the Department of Health and Ageing the authority to issue consents for the supply of therapeutic goods that do not conform to certain regulatory requirements, subject to specific conditions to safeguard public health. The recent consent given by the delegate of the Secretary for the supply of specific batches of mianserin hydrochloride and toremifene products by Merck Sharp & Dohme Australia Pty Ltd, despite non-compliance with certain labelling requirements, is an example of this regulatory flexibility aimed at ensuring continuous and safe supply of essential therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 ("the Act") applies to the regulation of therapeutic goods within Australia, encompassing the manufacture, supply, and advertising of these goods. Section 14 and 14A of the Act relate to the specific circumstances where consent may be granted for the supply of goods that do not conform to certain legislative requirements, as exemplified in the gazetted notice of January 16, 2013. In this particular case, the delegate of the Secretary of the Department of Health and Ageing granted consent for Merck Sharp & Dohme Australia Pty Ltd to supply two specific products, mianserin hydrochloride (TOLVON) 10 mg tablet blister pack and toremifene (as citrate) (FARESTON) 60 mg tablet blister pack, which did not conform with the requirements of Therapeutic Goods Order 69. This consent is limited to the specified batches and conditions, such as the use of labels bearing the details of the previous sponsor, Schering-Plough Pty Ltd, and does not authorise any changes to the products themselves. The consent extends nationally within Australia, as it is issued under the authority of the Commonwealth, and is applicable to the entities involved, namely Merck Sharp & Dohme Australia Pty Ltd. The Act’s reach is further extended through subordinate instruments, such as Therapeutic Goods Orders, which provide detailed specifications and requirements for therapeutic goods.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides a framework for regulating therapeutic goods in Australia. Sections 14 and 14A of the Act pertain to the approval of specific therapeutic goods that do not conform to certain regulatory standards, allowing for exceptions under particular conditions. In this case, the delegate of the Secretary of the Department of Health and Ageing has given consent for the supply of two products by Merck Sharp & Dohme Australia Pty Ltd that do not meet the requirements outlined in paragraph 3(2)(l) of Therapeutic Goods Order 69. Specifically, the carton labels for the products mianserin hydrochloride (TOLVON) 10 mg tablet blister pack and toremifene (as citrate) (FARESTON) 60 mg tablet blister pack still list the details of the previous sponsor, Schering-Plough Pty Ltd, instead of the new sponsor, Merck Sharp & Dohme Australia Pty Ltd. This consent is strictly conditional and applies only to the specified batches of the products: batch 115474 for mianserin hydrochloride (TOLVON) 10 mg tablet blister pack and batch 1481121 for toremifene (as citrate) (FARESTON) 60 mg tablet blister pack. Moreover, the labels used must bear the details of the previous sponsor, Schering-Plough Pty Ltd. No other changes have been made to the products themselves. The approval process and the conditions under which these products can be supplied are detailed in correspondence from the company dated December 12, 2011, signed by Merrin Tulloch, which outlines the process in place to ensure continuous customer contact with the Company as the new sponsor. Entities governed by the Act are required to adhere to specific obligations and requirements, particularly when dealing with therapeutic goods that do not conform to regulatory standards. Merck Sharp & Dohme Australia Pty Ltd must ensure that the labels for the specified batches of the products correctly reflect the details of the previous sponsor as outlined in the consent. Additionally, the company must maintain a robust process for continuous customer contact, as detailed in the correspondence signed by Merrin Tulloch. This includes ensuring that any communication and supply chain processes remain transparent and compliant with the Act’s requirements. Failure to comply with the conditions set forth in the Act can lead to significant consequences. Breaches of the Act may result in civil or criminal penalties, depending on the severity of the violation. The Act stipulates that certain offences carry specified penalties, and non-compliance can lead to legal action, fines, and other sanctions. The exact penalties are determined based on the specific nature of the breach, but the Act provides a clear framework to address non-compliance and protect public health and safety.